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ABSTRACT 
 
Background:  Androgen receptor (AR) is a protein in the human body that 
binds various steroidal androgens such as testosterone and causes specific 
anabolic and androgenic activities.  Current methods of androgen therapy are 
limited in use because of their inability to target anabolic versus androgenic 
activities.  Selective androgen receptor modulators (SARMs) are nonsteroidal 
AR ligands that hold clinical promise in that they have the ability to selectively 
target anabolic versus androgenic activities, because they have the ability to 
act as agonists and antagonists in various tissues.  Despite all that is known 
about SARM pharmacology, there is limited information about their structure, 
stability, and protein-protein interactions. 
 
Study Design and Methods:  The question arises of whether or not two known 
SARMs (007 and 014) differ in their biochemical properties when bound to AR.  
To explore the question of which complex is the most stable, AR-ligand 
complexes (i.e., AR-007 and AR-014) were formed with the SARMs and they 
were exposed to heat to determine if the two had different degradation rates.  
To determine differences in three-dimensional conformation, the complexes 
were degraded by typsin to explore if they yielded different patterns of 
degradation.  Finally, to determine whether or not the two complexes have 
different protein-protein interactions, heat shock protein 70 (hsp70) was 
measured via a Western blot technique to determine if the two complexes have 
different levels of association with hsp70. 
 
Results:  AR-007 degraded more quickly than AR-014 when exposed to heat.  
AR-007 and AR-014 were broken down by trypsin in a similar fashion.  AR-007 
and AR-014 seem to have a tighter and more coiled conformation than AR-DHT 
(dihydrotestosterone), which was used as a positive control, because AR-DHT 
was broken down more readily by trypsin than the AR-SARM complexes.  The 
AR-007 complex also had a stronger association with hsp70 than the AR-014 
complex. 
 
Conclusion:  The faster degradation of AR-007 when exposed to heat and its 
stronger association with hsp70 indicates that it is the least stable out of the 
two SARM complexes with AR.  We conclude that SARM-induced 
conformational changes in the AR contribute to their differing pharmacology 
from steroidal androgens.  These conformational changes are ligand-specific 
and affect the stability of the AR and its interactions with other intracellular 
proteins.
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Androgen Receptor Functions 
 
Androgen receptor (AR) is a protein that functions as an intracellular 
hormone receptor.  It specifically binds androgens, such as testosterone, which 
leads to the regulation of various bodily functions.  AR is expressed the 
strongest in certain types of tissues in the body including the prostate and 
epididymis in males, the adrenal gland, skeletal muscle, the liver, skin, and in 
the central nervous system (1).  There are two basic types of bodily functions 
that are regulated by AR:  androgenic activities, which include the development 
of male secondary characteristics (voice, hair, skin, etc.) as well as 
spermatogenesis, and anabolic activities, which include regulation of the size 
and strength of muscle and bone as well as regulation of the hematocrit (2).   
When testosterone is secreted by the body, it binds to AR and guides the 
expression of proteins associated with both androgenic and anabolic activities.  
Testosterone is considered a non-selective AR ligand because it stimulates 
androgenic and anabolic activities to an identical extent with similar potency. 
AR is a approximately 110 kDa in size.  The gene that codes for AR is 
located on the X-chromosome at the location of Xq11.2-12 (3).  Figure 1 shows 
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the structure of AR with its various regions.  The –NH2 terminal of AR is 
responsible for transcriptional activation of both full-length AR and 
constitutively active AR, which is full-length AR minus its ligand-binding 
domain (3).  Toward the center of the molecule is the DNA-binding domain, 
which allows AR to bind to portions of DNA in target tissues and turn on or 
turn off the transcription of proteins that regulate anabolic and androgenic 
activities in the body.  The ligand-binding domain (LBD) of AR, which is located 
in the –COOH terminal end, is where a ligand such as testosterone would bind 
to either activate or deactivate AR, causing it either to bind to DNA in the 
nucleus of the tissues it acts upon, leading to mRNA transcription and protein 
translation, or just the opposite. 
     
 
 
 
 
 
 
 
 
1.2 Ligands of Androgen Receptor 
The LBD of AR plays an important role in regulation.  When there is an 
agonist such as testosterone bound to the LBD then AR can do its job:  binding 
Figure 1:  Molecular structure of human androgen receptor.  Includes 
the location of AR on the X-chromosome, the exon breakdown, and the 
various domains of the molecule.  Taken from (10). 
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to DNA and causing an increase in androgenic and anabolic activities.  When 
there is an antagonist bound to the LBD of AR (or when the AR is unbound), 
then the androgenic and anabolic activities of the body are turned off (2).   
As was previously stated, testosterone is a major endogenous molecule 
that binds to AR at the LBD.  However, there are many different ligands besides 
testosterone that have been studied which can regulate the function of AR.  
One important molecule that is synthesized in the prostate and other organs is 
dihydrotestosterone (DHT).  DHT is a more potent metabolite of testosterone 
that functions as a regulator of male characteristics, a function similar to that 
of testosterone, but plays a larger role in the maturation and enlargement of 
the prostate (4).   DHT is considered an agonist, which is a ligand that turns on 
transcription and increases androgenic and anabolic activities in the body.   
Bicalutamide is another ligand that binds to the LBD of AR.  
Bicalutamide is not synthesized by the body, but has been developed as a drug 
to suppress the action of AR.  It is referred to as an antagonist, which turns off 
transcription and decreases androgenic and anabolic activity in the body.  
Bicalutamide is used in the treatment of prostate cancer. 
Although there are many other ligands that have been discovered, a 
particularly interesting class that has been developed are called the selective 
androgen receptor modulators (SARMs) which have the ability to act as both 
agonists and antagonists, possessing tissue selectivity. 
  
 
   
 8
1.3 Selective Androgen Receptor Modulators 
SARMs are a new class of synthetic non-steroidal molecules that mimic 
some but not all of the pharmacologic effects of testosterone.  Our laboratory 
discovered two SARMs, known as 007 and 014, that demonstrate tissue 
selective androgenic and anabolic activity.  Figure 2 shows the chemical 
structures of these SARMs.  Not only do SARMs demonstrate a high level of 
tissue selectivity when bound to the LBD of AR, but they show a high potency 
(5).  Although the pharmacologic effects of SARMs have been studied already, 
minimal information is known about their interactions with AR, their molecular 
mechanisms of activity, and their effects on AR stability.  This is a major 
research question that has arisen in the field of pharmacology and the study of 
AR.  Better understanding of the way that these SARMs work would allow for 
discovery of SARMs with improved activity, hopefully leading to the treatment 
of diseases involving the AR.   
 
 
  
    
     
 
 
1.4 Androgen Therapy 
SARMs hold much clinical promise when it comes to patients who need 
androgen therapy.  Androgen therapy is used for a wide variety of diseases and 
X 
Figure 2:  Structures of SARMs 007 
and 014.  Taken from (2). 
014: X=F 
007: X=NHCOCH3 
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ailments that occur in both men and women where androgens either function 
insufficiently or are not produced in an adequate amount.  Some of these 
conditions include hypogonadism, delayed puberty, anemia, primary 
osteoporosis, endometriosis, and various muscular diseases, to name a few (6).   
  There are a variety of issues when it comes to the administration of 
testosterone to a patient who has an inadequate amount.  First of all, it is 
worrisome to administer to women, due to the fact that they may develop 
undesirable male characteristics if given large enough doses (1).  A downfall of 
testosterone therapy in men is that, as previously mentioned, it may enlarge 
the prostate and worsen benign prostatic hyperplasia, a common disease in 
older men.  As androgens may also stimulate the growth of prostate cancer, 
treatment of men with undetected prostate cancer is another concern.  Acne is 
a common side effect in men and women due to the effects of testosterone on 
the skin.  Due to the fact that testosterone is not able to target specific tissues, 
it simply affects all tissues of the body, which leads to these side effects during 
treatment.   
Bicalutamide has proven to be a successful drug for the treatment of 
prostate cancer because of its antagonistic activity.  However, along with 
shrinking the prostate, it also causes muscle-wasting and other undesirable 
effects due to the fact that it does not selectively target the prostate, but it acts 
on all tissue receptors of AR (7).   
The advantage that SARMs have to offer is tissue selectivity.  When they 
are bound to the LBD of AR, they are able to mimic the beneficial effects of 
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testosterone, such as muscle growth, but avoid unwanted effects, such as 
prostate growth (2).  This is true due to the fact that SARMs have weak 
antagonist activity in the prostate and agonist activities in the muscle and 
bone.  This leads to the conclusion that SARMs can effectively be used to treat 
muscle-wasting conditions, hypogonadism, and age-related frailty without 
causing concern for prostate enlargement or stimulation of undetected prostate 
cancer.   
Although SARMs offer new alternatives for the use of androgen therapy, 
we understand very little about how they work.  Do SARMs interact differently 
with the AR than steroidal androgens?  Does the AR act or work in unique 
ways when bound to a SARM?  Are there differences in stability or protein 
interactions between AR bound to 007 and AR bound to 014?   
There are many different ways to approach the question of the stability of 
AR-ligand complexes.  Typically, less stable proteins degrade faster when 
exposed to heat.  The biochemistry of AR indicates that it changes its three-
dimensional conformation when bound to a ligand (6).  If there are differences 
in the way that AR coils and folds when it is bound to each of these SARMs, it 
leads to stability information about these complexes.  If they coil into a tighter 
three-dimensional structure, then they are less available for protease cleavage, 
and indeed more stable.  Also, looking at protein-protein interactions could be 
a useful tool.  If the AR-ligand complexes associate with more chaperone 
proteins when transported into the cell, then that suggests that it is a less 
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stable or less active complex due to the roles that chaperone proteins often play 
in protecting intracellular proteins from the harsh cellular environment. 
Some important research questions to address:  are there differences in 
stability between AR-007 and AR-014?  Are there different protein-protein 
interactions between the two complexes that could lead to the assumption that 
they have different stabilities and mechanisms of action?  Are there structural 
differences between AR-007 and AR-014 that could allow one complex to be 
more stable than the other?  Finding the answers to these questions could aid 
in the understanding of the mechanism of action of SARMs, and eventual 
development of even better drugs.   
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
 
2.1  Androgen Receptor Expression 
Although androgen receptor (AR) is expressed in a variety of human 
tissues, it is difficult to acquire enough of it to study in a laboratory.  There are 
two common techniques to overcome this hurdle.  The first is to use an 
immortalized cell line that expresses high concentrations of the AR.  The LnCap 
human cell line is an androgen-sensitive human prostate adenocarcinoma cell 
line (8).  Cells derived from the prostate, and especially prostate cancer cells, 
express a lot of the AR due to their dependence on androgens (i.e., testosterone 
and dihydrotestosterone) for growth.  These cells grow and divide rapidly in the 
laboratory and provide a replenishable source of AR.   
The second technique is use of the baculovirus Autographa californica 
expression system in Sf9 insect cells.  A. californica is pathogenic to many 
species of insect cells, and has the ability to form intracellular structures called 
polyhedrons, which have the ability to induce site-specific mutations on the 
insect genome via recombination of co-transfected cells (9).  One of the proteins 
that this system has been identified as being able to express is AR.  By 
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transfecting Sf9 insect cells with A. californica, laboratories are able to obtain a 
large enough sample of functionally active AR to study.  Another benefit of this 
system is that Sf9 insect cell derived AR has similar immunological and 
functional properties as its mammalian AR counterparts (10). 
 
2.2   Selective Estrogen Receptor Modulators 
Selective estrogen receptor modulators (SERMs) are synthetic 
compounds that have the ability to act as full agonists, mixed 
agonists/antagonists, or pure antagonists in tissues expressing estrogen 
receptors (7).  This means that they have the ability to mimic the effects of 
estrogen in some tissues while blocking it in others.  SERMs have been 
developed to the point where they are used successfully in the clinical setting.  
Selective androgen receptor modulators (SARMs), like SERMs, have the 
potential to act in the same manner, only with tissues in which androgens play 
a role.  By studying the mechanisms of action and the clinical benefits of 
SERMs, more ideas can be formulated about SARMs, which are not yet at the 
point to where they can be used clinically.   
SERMs act on estrogen receptor (ER) in tissues, while SARMs act on 
androgen receptor (AR) in tissues.  ER can be found in a variety of tissues such 
as breast tissue, and in the cardiovascular, skeletal, and central nervous 
systems.  Estrogens also play an important role in the reproductive system of 
females.   
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It is important to regulate the use of estrogens as treatment options 
because, although they have many positive effects, they have major negative 
effects as well.  Estrogens can effectively inhibit bone resorption, preventing 
osteoporosis, benefit the cardiovascular system preventing risk of coronary 
heart disease, and some studies even suggest they may have the ability to 
delay the onset of Alzheimer’s disease (11).  However, a major negative effect of 
estrogens is that there is still concern for the stimulation of breast cancer, in 
which the risk increases for women who are on estrogen therapy.  Much of 
these same concerns are applicable to the use of androgens for therapy options 
as well because, although they have positive effects in one area of the body, 
such as the muscles and bones, they may have detrimental effects on another, 
such as the prostate.  
SERMs offer a solution to these issues associated with the use of 
estrogen therapy.  They have the ability to act on the pituitary gland, leading to 
an increase in follicle-stimulating hormone, and the uterus in an agonist or 
antagonist fashion, while acting on breast tissue in an antagonist fashion, 
decreasing breast cancer risk (12).  Given all of the positive outcomes and 
therapeutic issues that SERMs have solved, the medical world is optimistic 
about the use of SARMs as a replacement for androgen therapy, and hope that 
they can yield similar beneficial results in the respective tissues that they act 
upon. 
By studying the mechanism of action of SERMs, it is possible that the 
mechanism of action of SARMs can be deciphered, if it acts in a similar 
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fashion.  SERMs function through chaperone proteins that serve as co-
activators and co-repressors in various cell types in which ER acts.  SERMs 
also function through the conformational change of ER when a SERM binds to 
it, which determines how strongly the SERM-ER complex recruits these 
chaperone co-activators and co-repressors (12).  When there is a high ratio of 
co-activators to co-repressors, the action of ER on its target tissue increases, 
whereas if there is a low ratio, ER will not have a strong effect on its target 
tissues.   
 
2.3 Benefits of Androgen Therapy for Women 
Even though many think of androgens, like testosterone, as male 
hormones, they have some important benefits for women also.  Androgens are 
produced in the ovaries, adrenal glands, and fat cells in women, and they are 
important for sexual drive in women.  Even though the use of androgen 
therapy for enhancement of the sexual drive in women has not yet been 
approved by the Food and Drug Administration, it has been approved for 
conditions such as Turner’s Syndrome, premature menopause, AIDS-related 
and age-related wasting conditions, and even improvement of sexual function 
(13).  
 Turner’s Syndrome (TS) is a condition in which a woman has only one X 
chromosome, instead of the two they should normally have.  This in turn 
causes underdeveloped female characteristics and a lower level of verbal 
intellectual ability, spatial cognition, working memory, organization, and 
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planning (14).  Androgens such oxandrolone have proven to be a beneficial 
treatment option in improving the cognitive shortcomings of women with TS 
(14).  However, oxandrolone has a 10-100 times lower affinity toward AR than 
testosterone or dihydrotestosterone and is not selective, meaning that its long-
term effects are unknown but likely similar to the endogenous steroidal 
androgens (15).  The use of SARMs could overcome these disadvantages 
because they have a stronger affinity toward AR, and have the potential for 
selective and hopefully better, long-lasting results.   
 Premature menopause is another condition that can be treated using 
androgen therapy.  Women affected by premature menopause typically have 
low libido, fatigue, and diminished well-being (16).  Testosterone replacement 
therapy has proven to be beneficial in improving these undesirable effects.  Due 
to the fact that there is an age-related decline in the production of testosterone 
by both the adrenal gland and the ovaries, this decline can be attributed as 
having an effect on the onset of menopause, playing a factor in causing these 
symptoms (17).   
 Another benefit of androgen therapy in women is in the way that it builds 
muscle mass and bone.  This is beneficial for both aging women and for AIDS 
patients, both of whom typically have lower muscle mass and bone density 
caused by their wasting conditions.  The use of androgens in these types of 
patients has proven to be beneficial, because androgens have the ability to 
strengthen and build muscle and bone (18).    
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 Androgen replacement therapy in women is an important treatment 
option for women with a vast variety of conditions.  Common side effects 
include skin conditions (such as greasy hair and skin, itchy scalp, and hair 
loss), and also a decrease in HDL-cholesterol and total cholesterol (15).  This is 
where the use of SARMs as an alternative to androgen replacement therapy 
could benefit women.  They have the potential to have the same positive, 
anabolic effects in women while avoiding the negative side effects (1).  
 
2.4 Biochemistry of SARMs 
 SARMs have the ability to not only bind to AR with a very high affinity, 
but they have the ability to cause it to act as either an agonist, turning on 
transcription, or an antagonist, turning it off (2).  The mechanism as to how 
this occurs is very complicated, and the biochemical interactions must be 
observed as to how this phenomenon takes place. 
 The SARMs 014 and 007 bind to AR with a very high affinity.  The reason 
for this is their ability to interact with hydrophobic and hydrogen bond 
partners in the LBD of the AR.  The structures of the SARMs needed to be R-
isomers at the alpha carbon when incorporating a thioether of sulfonyl linkage, 
have an electrophilic para-substituent or hydrogen bond partner on the B-
aromatic ring, have a nitro group in the para-substituent in the A-aromatic 
ring, and have a tri-fluoromethyl at the meta position of the A-ring (see figure 
2) (19).  This structure can have modifications made on other areas of the 
molecule, providing great flexibility in chemical design and synthesis.   
   
 18
 How is it that SARMs cause AR to act as an agonist and an antagonist?  
The answer likely lies in the fact that they have the ability to cause 
conformational changes in AR (20).  AR has 11 alpha-helices in its structure 
(3).  The helices are numbered up to 12; however, the number 11 helix is 
missing.  When steroid agonists such as testosterone or dihydrotestosterone 
bind to AR at the ligand-binding domain (LBD), helix 12 closes over the binding 
pocket, which makes an area of the AR available for coactivator interaction.  
On the other hand, when antagonists bind to the LBD, helix 12 does not fully 
close and the coactivator interaction site is not formed (19).  It is possible that 
the tissue selectivity of SARMs could depend on the unique way that they 
cause the structure of AR to change, causing the recruitment of coactivators or 
corepressors (20). 
 
2.5 Chaperone Proteins of AR 
AR also interacts with various intracellular proteins while it is being 
transported to the nucleus after ligand binding.  Since testosterone is a 
steroidal hormone, it has the ability to cross the cell membrane and enter the 
cytoplasm of cells.  Prior to testosterone or any other ligand being bound, AR 
forms complexes with specific chaperone proteins.  Two of these proteins are 
heat shock protein 70 (hsp70) and heat shock protein 90 (hsp90).  They aid in 
the movement of AR through the cytoplasm and to the nucleus along 
microtubular tracks (21).   
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Given the complexity of the nucleus, these heat shock proteins must be 
able to transport AR to the exact location in the genome at which it needs to 
act (22).  There is a signal transduction pathway within the nucleus that allows 
a hormone receptor, such as AR, to bind to its intended genomic location.  The 
exact mechanism for AR is not known; however, a similar hormone receptor, 
glucocorticoid receptor (GR) has a pathway that is thought to be similar to that 
of AR, as shown in figure 3.  With GR, the microtubules interact with a 
molecule called Dynein, which is bound by its intermediate chains to an 
immunophilin, which then reacts simultaneously with hsp70 and hsp90 (which 
is bound to molecule p23), both of which interact with the GR-ligand complex 
(23).  This complicated scheme is what allows GR to move through the 
cytoplasm and to its site of action.  Researchers hope that by studying this 
mechanism, they can come up with a similar mechanism and identify similar 
chaperone proteins for the transport of AR through the cytoplasm and to the 
nucleus.  
Figure 3:  GR movement along microtubules with 
associated chaperone proteins.  Taken from (23). 
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CHAPTER 3 
 
MATERIALS AND METHODS 
 
3.1 Methodology  
There are three goals that this study intends to achieve.  The first goal is 
to determine whether or not the stability of AR is affected by the ligand bound, 
whether it is dihydrotestosterone (DHT) or a Selective Androgen Receptor 
Modulator (014 or 007).  It is important to explore this research question 
because if there are differences in stability between these ligands, then it can 
be deduced that the conformational differences that affect protein-protein 
interactions and DNA interactions are likely to exist.  It might also help to 
explain observed differences in the pharmacologic effects of different ligands in 
different tissues.   
Another goal is to determine whether or not the level of AR-chaperone 
protein interaction is dependent on the ligand bound.  A higher level of protein-
protein interactions will lead to the conclusion that one complex is more stable 
than other.  A higher level of protein-protein interactions may indicate that that 
complex is less stable than one that has less protein-protein interactions, 
because proteins typically use chaperone proteins as a stability factor for their 
journey through the cytoplasm and into the nucleus of cells.  Also, are there 
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ligand-specific protein-protein interactions for AR?  Different protein-protein 
interactions will indicate that these AR-ligand complexes have different 
mechanisms of traveling through the cytoplasm and into the nucleus.  This will 
indicate that the two SARMs may cause AR to behave in slightly different ways.   
Finally, we examined the three-dimensional structure of AR change when 
bound to each of the three ligands.  Different conformational changes could 
indicate that each of the ligands could cause AR to function in different ways.  
It could also lead to conclusions about the stability of each of these AR-ligand 
complexes.  A tighter, more coiled three-dimensional structure would likely be 
more stable than a looser one, because it is less likely to be degraded by 
proteases and other degradation factors.   
 
3.2 Design, Data, and Instrumentation 
3.2.1 Cell Preparation 
In order to isolate a sample of AR that could be used to investigate the 
research questions, it needed to be isolated from certain types of cells in a 
maximal amount.  The cells that were used for all experiments were Sf9 insect 
cells, because they have the ability to express AR in a large quantity.  The cells 
were grown in 90 mL of Grace's Insect Cell Media, supplemented with 10% FBS, 
to a concentration of 2.0 x 106 cells/mL.  After the cells reached the desired 
density, they were then divided into two Erlenmeyer flasks.  After that, 9 mL of 
high-titer AR baculovirus stock was added to each flask.  The cells were then 
infected with the baculovirus Autographa californica so that they would 
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strongly express AR (10).  The AR construct contained a hexahistidine (His6) tag 
to simplify purification.    
The Sf9 cells with amplified AR were cultured and treated with various 
ligands.  The cells that were used for the following experiments were divided 
into five different samples:  cells treated with Bicalutamide (an antagonist), 
cells treated with DHT (an agonist), cells treated with SARM 014, cells treated 
with SARM 007, and cells treated with no ligand at all (negative control).  The 
ligand treatment conditions (also known as the standard conditions) consisted 
of the addition of 1uM of ligand to the cultured cells after 24 hours of AR 
baculovirus infection, and then again 48 hours after baculovirus infection.  The 
cells were isolated via centrifuge, and stored at -80 degrees Celsius until 
further use.   
 
3.2.2 Protein Purification 
The first step of the protein purification was cell lysis.  The purpose of 
lysing the cells was to extract the AR protein from the Sf9 insect cells so that it 
could be further purified.  First, each 15 mL sample was treated again with 1 
ul/mL of their prospective ligands (Bicalutamide, DHT, 014, 007, or no ligand), 
to give a final concentration of ligand of 1 uM, after being re-suspended in 100 
mL of Protein Lysis/Wash Buffer containing Hepes and a protease inhibitor, to 
prevent the AR protein from being digested prematurely.  The suspended cells 
were subjected to four freeze-thaw cycles in dry ice/100% ethanol to physically 
lyse the cells by breaking down the cellular membrane, which caused the 
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contents in the interior of the cells to be released.  The cell lysate was then 
centrifuged at 18,000 RPM for 40 minutes at 4 degrees Celsius.  The 
supernatant, which was the portion containing AR along with other cell 
proteins, was collected and stored at -80 degrees Celsius for later use. 
The next step of the protein purification was TALON® Metal Affinity 
Chromatography.  The TALON® metal affinity resin was equilibrated with 10 
mL of Hepes Protein Lysis/Wash Buffer containing the prospective ligands for 
each sample and a protease inhibitor, and then centrifuged to pellet the resin.  
The cell lysate from the ultracentrifuge was then divided into two halves, which 
were incubated with the pre-equilibrated resin for one hour each at 4 degrees 
Celsius by gentle agitation.  This allowed for the AR protein to stick to the 
resin, thus extracting it from the cell lysate, and theoretically away from the 
other proteins that were in the sample.  The resin was centrifuged and washed 
with 10 mL Hepes Protein Lysis/Wash Buffer, again containing the prospective 
ligands, five times for each sample.  The resin was transferred to a column, and 
the absorbed proteins were eluted with Elution Buffer containing 25 mM 
imidazole and 50 mM imidazole.  A total of 9-10 elution portions were collected 
for each sample.  The protein portions were stored at -80 degrees Celsius until 
further use.   
The next step in the protein purification assay was to confirm the level of 
purity using SDS Polyacrylamide Gel Electrophoresis.  The 9-10 elution 
portions of proteins from the five different samples were subjected to SDS 
polyacrylamide gel electrophoresis (SDS-PAGE).  This process separated the 
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various proteins in the elution portions based on their electrophoretic mobility.  
The gels were stained with a Coomassie stain, and photos were taken of each 
gel.  The purpose of this procedure was to verify the purity of the AR protein in 
each of the elution portions. 
   The yield of the various elution portions of proteins was determined via 
quantification using the Bio-Rad Protein® assay.  The Bradford assay was 
used, which is a colorimetric assay based on the color change of Coomassie 
Brilliant Blue® dye, which measures total protein concentration of a specific 
sample.  The “standard assay” conditions were used because the concentration 
of the protein was expected to be between 20 and 140 ug/mL.  If the protein 
concentrations were above 140 ug/mL, dilutions of the elution portions were 
made.  Absorbance levels were read at a wavelength of 595 nm.  Standards of 
known concentrations of bovine serum albumin (BSA) were used to match the 
wavelength readings to the actual protein concentrations.  Three different 
dilutions of BSA in water were used to make the standards:  62 ug/mL, 125 
ug/mL, and 250 ug/mL.            
 
3.2.3 Stability Experiments 
 The next portion of the experiment included an exploration of 
conformational information and stability of AR when it is bound to different 
ligands.  This portion of the experiment attempted to answer the question of 
whether or not the stability of androgen receptor is affected by the ligand 
bound.  The stability of the various AR-ligand complexes and the affinity to 
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which each ligand binds to AR was explored to determine whether or not 
different ligands create different conformational changes.   
In these experiments, the various AR-ligand complexes were subjected to 
heat for various amounts of time.  Considering that heat normally has the 
effect of denaturing proteins, if the AR-ligand complexes remained intact for a 
long period of time, it suggests that they are more stable than those that 
degraded.   
 One elution portion of four of the five samples of purified AR was selected 
for further analysis:  AR-no ligand (second fraction, 50 mM imidazole), AR-DHT 
(fifth fraction, 25 mM imidazole), AR-014 (first fraction, 50 mM imidazole), and 
AR-007 (first fraction and second fraction, 50 mM imidazole).  The specific 
fractions were chosen because according to the SDS-PAGE gels, they were the 
purest of all of the protein fractions, containing virtually only AR and no other 
proteins.  The first stability experiment entailed establishing a negative control 
by subjecting a small portion of the AR-no ligand protein to 37 degree Celsius 
heat for four different time periods:  0 min, 15 min, 30 min, and 60 min.     
 The second stability experiment involved subjecting 1.05 ug of the AR-
007, AR-014, and AR-DHT complexes to 37 degree Celsius heat for 0 hours, 6 
hours, 9 hours, and 12 hours.  The third stability experiment involved a 
repetition of the second experiment, but using 1.15 ug of the samples and 
subjecting them to 37 degree Celsius heat for 0 hours, 12 hours, 24 hours, and 
36 hours.  The samples from all three experiments were subjected to SDS-
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PAGE analysis to determine the percentage of each sample that had degraded 
over time. 
 After the gels were imaged, a program called Image J® was used to 
quantify the AR protein bands for each sample on each gel.  These values are a 
reflection of peak intensities of the AR band as it compares to the rest of the 
proteins in the same lane.  Theoretically, these values should reflect the 
relative amounts of AR remaining in each sample.  
 
3.2.4 Protein-Protein Interaction Experiments 
 To examine whether or not protein-protein interactions are different 
amongst the various AR-ligand complexes, another experiment was conducted.  
A protein that is hypothesized to be associated with AR is heat shock protein 
70 (hsp70).  The goal of this experiment was to determine if hsp70 was more 
strongly associated with AR-DHT, AR-007, or AR-014.  If it associated more 
strongly with one over the other, then it could be concluded that that complex 
is less stable or at least conformationally different.   
The AR protein for this experiment was isolated from the cell lysates of 
the Sf9 insect cells, treated with baculovirus Autographa californica and with 
DHT, 007, and 014 at the standard conditions.  The three cell lysates were 
subjected to immunoprecipitation, which is a technique that uses an antibody 
specific to the desired protein (AR) to precipitate out that protein.   
 The immunoprecipitation technique involved pre-clearing 2.0 mg of 
lysate from each sample by adding 1.0 ug of a control IgG and 50 uL of protein-
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A agarose after one wash with a binding buffer.  After the wash, each sample 
was brought to a total volume of 500 uL by adding binding buffer.  The 
samples were incubated for one hour at 4 degrees Celsius.  Each sample was 
centrifuged at 2500 rpm for 30 seconds at 4 degrees Celsius.  The supernatant 
was transferred to a microcentrifuge tube, combined with 2 ug of the primary 
AR antibody (labeling the –COOH terminal of the protein), and incubated for 24 
hours at 4 degrees Celsius with rocking.  Then, 50 uL of protein-A agarose was 
added after one wash with the binding buffer.  The samples were then 
incubated at 4 degrees Celsius for two hours.  The immunoprecipitates were 
collected via centrifugation, washed three times with PBS, resuspended in 
Electrophoresis Sample Buffer®, and boiled.  At this point, the samples were 
stored at -20 degrees Celsius until later use.    
 A Western blot method was used to detect the AR protein in each sample, 
by using gel electrophoresis to separate proteins by shape and size.  The 
samples were labeled by a rabbit anti-AR antibody at the –COOH terminal, and 
then a secondary anti-rabbit antibody.  Results were obtained by developing 
the membranes on a film.  After evidence suggested that AR was indeed present 
in equal quantities in all samples, the Western blot was repeated, only this 
time samples were labeled by an anti-hsp70 antibody.  Results were examined 
to determine if different amounts of hsp70 were associated with AR-DHT, AR-
007, and AR-014. 
 
 
   
 28
3.2.5 Partial Proteolysis 
 In order to evaluate the stability and conformation of AR-007, AR-014, 
and AR-DHT, a partial proteolysis experiment was performed.  Pure protein 
samples of AR (the same samples that were used in the stability experiments) 
were used for this experiment.  The three AR samples (1 ug) treated with DHT, 
007, and 014 were each combined with 0.02 ug of trypsin, an enzyme that 
digests proteins.  Each sample was divided into four different sub-samples:  
one that was not treated with trypsin, one that was treated for 10 minutes, one 
that was treated for 20 minutes, and one that was treated for 30 minutes.  
Results were examined using Western blotting:  once using an antibody 
labeling the –NH2 terminal and once using an antibody labeling the –COOH 
terminal of the protein.  The films were examined to determine if different 
protein products were seen when each of the AR-ligand complexes was 
degraded.  This information would serve to evaluate whether or not the three 
proteins had different conformations and stabilities once exposed to the 
protein-destructive trypsin.   
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CHAPTER 4 
 
RESULTS AND CONCLUSION 
 
4.1  Results 
 
4.1.1  Stability Experiments 
Three pure protein fractions were used for the stability experiments.  The 
purest protein fractions were used because the idea was to use a sample that 
contained virtually only AR with no other proteins.  By using only AR, it could 
be reasonably certain that interfering proteins would not skew the data in any 
way or make the data invalid.  The pure protein fractions that were used for all 
of the following experiments are shown in figure 4 (AR-014), figure 5 (AR-007), 
and figure 6 (AR-DHT).  
Figure 4: Pure AR-014 Samples Figure 5: Pure AR-007 Samples 
F1 50 mM 
F1 50 mM F2 50 mM 
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Another sample was used as a negative control.  This sample consisted of 
only AR, and it did not have a ligand to make a complex with.  As can be seen 
in Figure 7, AR when it is not complexed with a ligand is not very stable.  It 
was difficult to obtain a sample that had enough pure AR in it to carry out the 
experiment with no ligand present.   
 
 
 
 
 
 
 
 
 
 
Figure 6: 
Pure AR-DHT Samples 
F5 25 mM 
F2 50 mM 
Figure 7:  Pure AR-No Ligand Samples 
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It was important to ensure that each sample was made up of a pure 
sample of AR, complexed to one of three ligands, because it could then be said 
that the sample was essentially made up of all AR-ligand complexes, and 
minimal background protein.  This made the experiment more accurate and 
meaningful. 
 It was also important to determine the concentrations of the protein 
samples that were used in the experiments, to ensure that equal amounts of 
each sample were being used.  The concentrations were determined using the 
Bio-Rad Protein® assay, as described above.  The concentrations can be found 
in Figure 8. 
 
FIGURE 8:  TABLE OF PROTEIN CONCENTRATIONS  
USED FOR STABILITY EXPERIMENTS 
Protein 
Fraction 
AR-014 
(F1 50 mM) 
AR-007 
(F1 50 mM) 
AR-007 
(F2 50 mM) 
AR-DHT 
(F5 25 mM) 
AR-No 
Ligand 
(F3 50 mM) 
Concen-
tration 
0.077 
ug/uL 
0.142 
ug/uL 
0.074 
ug/uL 
0.119 
ug/uL 
0.067 ug/uL 
 
 
The negative control experiment involved exposing 4.28 ug of the AR-no 
ligand sample to 37 degrees Celsius for 0 minutes, 15 minutes, 30 minutes, 
and 60 minutes.  The samples were subjected to SDS-PAGE analysis and 
results in figure 9 were obtained.  The results suggest that AR degrades readily 
when it is not complexed with a ligand.  Thus, ligands increase the stability of 
AR in general. 
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The next question that was addressed during this experiment was which 
ligands cause AR to be the most stable, or are there even any differences in 
stability between them?  Figure 10 describes the conditions of the first stability 
experiment.  Figures 11 and 12 describe the results of the experiment via SDS-
PAGE analysis. 
Figure 10:  Stability Experiment 1 Conditions  
Fraction Time Period 
At 37 degrees 
Concentration 
(ug/ul) 
Volume (ul) Amount of 
AR added 
(ug) 
AR-014 
F1 50 mM 
0 hr, 6 hr, 
9 hr, 12 hr 
0.077 13.6 1.05 
AR-007 
F2 50 mM 
0 hr, 6 hr, 
9 hr, 12 hr 
0.074 14.2 1.05 
DHT 
F5 25 mM 
0 hr, 6 hr, 
9 hr, 12 hr 
0.119 8.82 1.05 
Figure 9: 
Stability Experiment Results with 
AR-No Ligand 
Androgen 
Receptor 
          0 min        15 min       30 min      60 min 
   
 33
  
 
 
 
 
 
 
 
 
 
 
 
The results of the SDS-PAGE gels were confirmed via quantification.  
This was done via a program called Image J® which uses relative band 
intensities as a measurement tool.  When the relative band intensities were 
graphed as a function of percent of the sample remaining vs. time at 37 degrees 
Celsius.  The results can be observed in figure 13.  The graph suggests that 
AR-007 degrades at a faster rate than AR-014 and AR-DHT. 
             007      014 
  0hr   6hr  9hr 12hr  0hr 6hr  9hr 12hr 
DHT 
              0hr     6hr      9hr   12hr 
Figure 11:  Stability Experiment 1 
Results with AR-014 and AR-007 
Figure 12:  Stability Experiment 1 
Results with AR-DHT 
AR 
AR 
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In order to confirm these results, the stability experiment was repeated 
with similar conditions.  However, this time, the AR-ligand complexes were 
exposed to 37 degree Celsius heat for longer periods of time.  A slightly larger 
amount of AR was added also.  Figure 14 describes the conditions used in this 
experiment.  Figures 15 and 16 describe the results obtained for stability 
experiment 2. 
 
 Figure 14:  Stability Experiment 2 Conditions  
Fraction Time Period 
At 37 degrees 
Concentration 
(ug/ul) 
Volume (ul) Amount of 
AR added 
(ug) 
AR-014 
F1 50 mM 
0 hr, 12 hr, 
24 hr, 36 hr 
0.077 15.0 1.15 
AR-007 
F1 50 mM 
0 hr, 12 hr, 
24 hr, 36 hr 
0.142 8.1 1.15 
DHT 
F5 25 mM 
0 hr, 12 hr, 
24 hr, 36 hr 
0.119 9.7 1.15 
F i g u r e  1 1 :   S t a b i l i t y  E x p e r i m e n t  1  G r a p h
y  =  - 2 . 1 9 1 4 x  +  1 0 3 . 2 2
y  =  - 3 . 4 2 1 x  +  1 0 0 . 9 9
y  =  - 5 . 5 8 5 7 x  +  9 7 . 7 2 9
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
0 5 1 0 1 5
T im e  a t  3 7  d e g r e e s  (h r s )
P
e
rc
e
n
t 
re
m
a
in
in
g
A R - 0 0 7
A R - 0 1 4
A R - D H T
Figure 13:  Stability Experiment 1 Graph 
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These results seem to be very similar those obtained from the first 
stability experiment.  Figure 17 shows these results after quantification using 
Image J®.  In both studies, AR-007 was the least stable of the receptor 
complexes, while AR-DHT and AR-014 showed better and approximately equal 
stability to heat. 
 
             007      014 
0hr 12hr 24hr 36hr 0hr 12hr 24hr 36hr 
Figure 15:  Stability Experiment 2 
Results with AR-014 and AR-007 
Figure 16:  Stability Experiment 2 
Results with AR-DHT 
DHT 
               0hr  12hr  24hr 36hr 
F i g u r e  1 5 :   S t a b i l i t y  E x p e r i m e n t  2  G r a p h
y  =  - 1 . 4 2 4 2 x  +  1 0 3 . 0 1
y  =  - 1 . 2 9 8 3 x  +  9 7 . 1 2
y  =  - 2 . 2 4 x  +  1 0 4 . 2 2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
0 1 0 2 0 3 0 4 0
T i m e  a t  3 7  d e g r e e s  ( h r s )
P
e
rc
e
n
t 
re
m
a
in
in
g
S A R M  0 0 7
S A R M  0 1 4
D H T
Figure 17:  Stability Experiment 2 Graph 
AR 
AR 
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4.1.2 Protein-Protein Interaction Experiments 
To examine whether or not the various AR-ligand complexes displayed 
different protein-protein interactions, immunoprecipitatates, which contained 
AR and any proteins closely associated with it, were analyzed via Western 
blotting.  The first set of data that was collected involved the antibody labeling 
of AR in each of the samples.  The purpose of this was to indicate that AR was 
indeed present in all immunoprecipitation samples in equal amounts.  A 
negative control was used to indicate that there was a minimal amount of non-
specific antibody binding in the samples.  For the negative control, no primary 
antibody was added to the Western blot membrane.  In this instance, 2.0 mg of 
AR-007 was used as the negative control, but it theoretically did not matter 
which sample was chosen.  Positive controls of 5% of the cell lysates were used 
to confirm that AR was present initially, before immunoprecipitation, in all 
samples used.  All of the immunoprecipitation products had 2.0 mg of cell 
lysate, yielding approximately the same amount of product for each sample.  
The results in figure 18 were obtained for the western blot labeled with anti-AR. 
 
 
 
 
 
 
 
                       
   Negative             IP Samples           Positive Controls   
    Control         007    014   DHT      DHT    007    014 
  Androgen 
Receptor 
Figure 18:  Western Blot with antibody labeling of 
Androgen Receptor  
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 It can be confirmed from these results that AR was indeed present in all 
samples, seen at about 110 kDa.  The negative control shows that a negligible 
amount of non-specific antibody binding contributes to the band intensities.  The 
next step in the experiment was to determine whether or not heat shock protein 70 
(hsp70) associated with the AR-ligand complexes.  Since hsp70 is a protein thought 
to be associated with AR, it should be present in all samples.  The results in figure 
19 are those that were obtained when the Western blot membrane was probed with 
an anti-hsp70 antibody.  A large amount of hsp70 was found in all samples, but 
appeared to differ based on the ligand bound to the AR. 
                       
          Negative         IP Samples        Positive Controls   
           Control        007  014 DHT      DHT  007  014 
  
Heat Shock 
Protein 70 
Figure 19:  Western Blot with antibody labeling of 
Heat Shock Protein 70  
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 To confirm these results, the bands were quantified using Image J® and 
compared with one another in terms of the ratio of hsp70:AR.  Considering 
about the same amount of AR was present in all samples, the higher the ratio 
of hsp70:AR then the more AR-hsp70 association was present.  The results can 
be seen in figure 20.  The graph confirms the results from the Western blot 
films in that it suggested that AR-007 associated more strongly with hsp70 
than the other two AR-ligand complexes. 
 
 
 
 
 
 
 
 
4.1.3 Partial Proteolysis 
In order to examine whether AR-DHT, AR-007, and AR-014 have different 
three-dimensional orientations, a partial proteolysis experiment was 
conducted.  The idea was to determine if trypsin, an enzyme which degrades 
proteins, clips and cuts up these three AR-ligand complexes in different ways.  
If it does, then it suggests that these three complexes indeed have different 
three-dimensional conformations.  Pure AR protein samples were used for this 
experiment.  The three samples, AR-014, AR-007, and AR-DHT were degraded 
0 .3 2 7
0 .0 4 7
0 .0 2
0
0 .0 5
0 .1
0 .1 5
0 .2
0 .2 5
0 .3
0 .3 5
A R - 0 0 7  A R - 0 1 4  A R -D H T
A R - l ig a n d  C o m p le x e s
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o
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f 
H
S
P
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Figure 20:  Protein-Protein Interactions Graph 
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with trypsin for a total of 0 minutes, 10 minutes, 20 minutes, and 30 minutes.  
The patterns of degradation were observed using Western blot analysis.  There 
were two sets of data in this experiment.  The first set of data came from 
antibody labeling at the –COOH terminal, and the second came from antibody 
labeling at the –NH2 terminal.  The purpose of labeling both ends was to get a 
better picture of how exactly the proteins were being degraded.  The results of 
the –COOH labeled terminal are shown in figure 21 and figure 22 and the 
results of the –NH2 labeled terminal are shown in figure 23 and figure 24. 
 Figures 21-24 suggest that at the C-terminal, AR-007 and AR-014 have 
tigher, more coiled conformations than AR-DHT because they avoid 
degradation by trypsin better for longer periods of time.  The darker and more 
prominent band at the top of the gel, which represents the largest protein 
fraction, shows that the sample contains a larger portion of protein that has 
not been degraded by trypsin.  Similar results at the N-terminal support this 
theory.   
 
 
 
 
 
 
 
 
  0 minutes 
        007  014  DHT 
Figure 21:  Partial proteolysis results labeled at the C-terminal 
Androgen 
receptor 
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Figure 22:  Partial proteolysis results labeled at the C-terminal 
Figure 24:  Partial proteolysis results labeled at the N-terminal 
      Positive 20 minutes 30 minutes 
      Control   007 014 DHT   007 014 DHT 
  0 minutes 
         007 014 DHT  
  10 minutes 
         007 014 DHT  
Positive  20 minutes         30 minutes 
 control 007 014 DHT      007  014 DHT 
AR AR 
AR 
AR 
AR AR 
Figure 23:  Partial proteolysis results labeled at the N-terminal 
      10 minutes 
  007  014  DHT 
AR 
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4.2 Discussion 
The results from the stability experiments showed an interesting pattern.  
For the negative control, where AR was not complexed with a ligand, there was 
hardly any sign of a band on the SDS-PAGE gel indicating that there was AR in 
the sample.  There was a slight band at time point 0 minutes, but it diminished 
quite quickly as time went on.  It appears that all of the AR was degraded after 
only 30 minutes.  This leads to the conclusion that AR is broken down readily 
when it is not complexed to a ligand.  Therefore, ligands in general cause AR to 
be more stable than when it is by itself (i.e., unbound). 
In the first stability experiment, the main observation was that, as time 
progressed, the AR-DHT and AR-014 complexes seemed to be more stable.  
They appeared to have less degradation during the 37 degree Celsius heating 
period, which was shown by darker bands on the SDS-PAGE gel and 
subsequent image analysis.  There were more of the AR-DHT and AR-014 
complexes left at 12 hours than the AR-007 complex, which appeared to have a 
less intense band and therefore a smaller relative concentration at 12 hours.   
Similar results were obtained in the follow-up stability experiment with 
the longer time points.  Again, AR-007 seemed to degrade at a quicker rate 
than AR-014 and AR-DHT.  Therefore, it can be concluded that the AR-014 and 
AR-DHT complexes are more stable than the AR-007 complex because they 
were able to withstand the heat exposure for a longer period of time, while AR-
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007 degraded and was not able to withstand the heat exposure.  The graphs in 
figure 13 and figure 17 confirm these results. 
In the protein-protein interactions experiment, where each AR-ligand 
complex was examined to see their amounts of association with heat shock 
protein 70 (hsp70), another interesting result was obtained.  It appeared that 
the band intensities of hsp70 were weakest for the AR-014 and AR-DHT 
samples than for the AR-007 complex.  These results indicate that hsp70 
associates more closely with AR-007 than with AR-014 and AR-DHT, which 
was concluded as a result of the darker band of hsp70 with AR-007.  The 
quantitative data image analysis confirmed that AR-007 associated more 
strongly with hsp70 than the other two AR-ligand complexes. 
 The data in the first two experiments correlate well with one other.  The 
results from the stability experiments showed that AR-007 is less stable than 
AR-014 and AR-DHT because it breaks down readily when exposed to heat.  
The results from the protein-protein interactions experiment also indicate that 
AR-007 is a less stable complex because it had the strongest association with 
hsp70.  Typically, less stable molecules associate with more chaperone proteins 
when they travel through the cellular environment.  More proteins provide 
better protection for the molecule so that it can avoid degradation.     
 The purpose of the partial proteolysis experiment was to obtain more 
information about the three-dimensional structures of AR-007, AR-014, and 
AR-DHT.  According to the results in figure 21, AR-DHT is broken down into 
the smallest fractions at the –COOH terminal.  This can be concluded because 
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the largest band, or the top band, is the faintest.  AR-007 and AR-014 seem to 
have approximately the same intensity at the top band at all time points, which 
indicates that a larger portion of the intact AR is present.  This suggests that 
they have a tighter, and more coiled conformation than AR-DHT because they 
are not being easily digested by the trypsin.  However, this possible conclusion 
conflicts existing data regarding the known conformational changes that occur 
with DHT and SARMs.  A further experiment could be performed to determine 
why AR-007 and AR-014 are more resistant to trypsin proteolysis.  This may 
lead to information about their functions and how they can act as both 
agonists and antagonists.    
 Looking at the results from the –NH3 terminal in figure 22, at 10 minutes 
all of the bands are slightly fainter, but they are in approximately equal 
intensities.  This suggests that all of the AR complexes have a more coiled 
conformation at the –NH3 terminal as compared to the –COOH terminal.  
Looking at the 20 minute time point, AR-007 has a heavier band at the top 
than AR-014 and AR-DHT.  However, at the 30 minute time point, AR-007 and 
AR-014 have approximately the same band intensities at the top band.  In both 
the 20 and 30 minute time points, AR-DHT appears to have been degraded 
more so than the AR-007 and AR-014 samples.  Again, this leads to the 
conclusion that AR-007 and AR-014 are more stable and appear to have a 
more coiled conformation in general than AR-DHT. 
 These results suggest that SARMs induce unique AR conformations that 
affect its stability, interactions with other intracellular proteins, and perhaps 
   
 44
even pharmacologic action and tissue selectivity.  The studies reported herein 
are preliminary in nature, but suggest that detailed characterization of the 
biophysics of AR will eventually shed light on the molecular mechanisms of 
these exciting new drugs. 
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